Bionano Genomics (BNGO) Other Non-Current Liabilities (2017 - 2026)

Bionano Genomics has reported Other Non-Current Liabilities for 8 years, with the latest figure at $5.8 million in Q2 2024.

• Quarterly Other Non-Current Liabilities fell 60.37% year-over-year to $5.8 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $5.8 million (down 60.37% YoY) and the FY2023 annual result came in at $10.9 million, down 16.04% from the prior year.
• Other Non-Current Liabilities declined to $5.8 million in Q2 2024 per BNGO's latest filing, from $10.2 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $14.9 million in Q3 2023 and troughed at $75000.0 in Q3 2020.
• A 5-year average of $9.2 million and a median of $10.6 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2021 and 2024: Other Non-Current Liabilities jumped 209.33% in 2021, then plunged 60.37% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $75000.0 in 2020, then surged by 11988.0% to $9.1 million in 2021, then jumped by 43.06% to $13.0 million in 2022, then retreated by 16.04% to $10.9 million in 2023, then slumped by 46.98% to $5.8 million in 2024.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $5.8 million, $10.2 million, and $10.9 million for Q2 2024, Q1 2024, and Q4 2023 respectively.